You just read:

Shire's OPUS-3 Phase 3 Trial with Lifitegrast Meets Primary and Key Secondary Endpoints, Significantly Reducing Patient-Reported Symptoms for Dry Eye Disease

News provided by

Shire plc

27 Oct, 2015, 11:48 GMT